Cal­cu­lus Cap­i­tal en­hances life sci­ences port­fo­lio

BioSpectrum (India) - - WORLD NEWS -

Pri­vate equity firm Cal­cu­lus Cap­i­tal, a lead­ing EIS and VCT in­vestor, has fur­ther ex­panded its life sci­ences port­fo­lio, by in­vest­ing £2.5 mil­lion in Cam­bridge-based Axol Bio­science (Axol), a provider of stem cells pro­duced from re­pro­grammed hu­man blood and tis­sue cells.

Axol sup­plies the world’s top pharma com­pa­nies, biotech and re­search in­sti­tu­tions with sus­tain­able, phys­i­o­log­i­cally rel­e­vant hu­man de­rived cell cul­ture mod­els for pi­o­neer­ing re­search and drug dis­cov­ery ap­pli­ca­tions. By har­ness­ing ad­vances in stem cell bi­ol­ogy, Axol is able to gen­er­ate self-re­new­ing cell-lines spe­cific to any part of the hu­man body from healthy and un­healthy tis­sue.

Im­por­tantly, Axol’s unique and in­no­va­tive ap­proach to this process en­sures that each cell line is iden­ti­cal to its pre­vi­ous pro­duc­tion batch, main­tain­ing the high qual­ity and the con­sis­tency re­quired for the de­vel­op­ment of novel ther­a­peu­tics.

Once a new cell line is devel­oped from a healthy or un­healthy tis­sue source, it is added to Axol’s suite of ‘off the shelf’ prod­ucts avail­able via their website. The com­bi­na­tion of these prop­er­ties means that the re­pro­grammed stem cells devel­oped by Axol are an es­sen­tial re­search tool for the de­vel­op­ment of new treat­ments for se­ri­ous ill­nesses and dis­eases, in­clud­ing Alzheimer’s and Hunt­ing­ton’s.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.